Drug Profile
SPR 206
Alternative Names: EVER-206; SPR-206Latest Information Update: 01 Mar 2024
Price :
$50
*
At a glance
- Originator Northern Antibiotics
- Developer Everest Medicines; Evotec SE; Spero Therapeutics
- Class Amides; Amines; Anti-infectives; Antibacterials; Benzene derivatives; Chlorinated hydrocarbons; Polymixins
- Mechanism of Action Bacterial outer membrane protein modulators; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Gram-negative infections
- Preclinical Acinetobacter infections
- No development reported Intra-abdominal infections
Most Recent Events
- 28 Feb 2024 US FDA approves IND application for SPR 206 in Gram-negative infections
- 11 Oct 2023 Pharmacokinetics and adverse events data from a phase I trial in Renal impairment presented at the IDWeek 2023 (IDW-2023)
- 22 Aug 2023 Everest Medicines expects NDA or BLA approval for SPR 206 for Gram-negative bacterial infections in 2025 and beyond (Everest Medicines pipeline, August 2023)